CHRYSALIS
CHRYSALIS was the first human study of amivantamab, an antibody that grabs both EGFR and MET; its cohort of people with EGFR exon 20 insertion lung cancer responded well enough to earn the drug its first approval.
Overview
CHRYSALIS is the phase 1 dose-escalation and expansion study of amivantamab, a bispecific antibody against EGFR and MET, in advanced non-small-cell lung cancer. Expansion cohorts tested the antibody alone in EGFR exon 20 insertion disease after platinum chemotherapy, and in combination with the third-generation EGFR inhibitor lazertinib or with chemotherapy in other EGFR-mutant settings.
The exon 20 insertion cohort, a group for which conventional EGFR inhibitors work poorly, showed a clinically meaningful response rate with durable responses, and amivantamab received accelerated approval in the United States in May 2021 for that indication. The combination cohorts with lazertinib provided the rationale for the phase 3 MARIPOSA and MARIPOSA-2 trials.
Similar pages
not linked directly; found by shared links- TrialCheckMate 227
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
- TrialKEYNOTE-407
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
- TrialPACIFIC-2
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
- TrialDESTINY-Lung01
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
- TrialEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Shares Lazertinib, Amivantamab, Johnson & Johnson, EGFR-mutated non-small-cell lung cancer.
- TrialCARTITUDE-6
Shares Johnson & Johnson and the tag subtype-trials.
- TrialAQUILA
Shares Johnson & Johnson and the tag subtype-trials.
- TrialRESONATE-2
Shares Johnson & Johnson and the tag subtype-trials.